دورية أكاديمية
أعرض في EDS

Evaluation of patients with implantable cardioverter-defibrillator in a Latin American tertiary center.

التفاصيل البيبلوغرافية
العنوان: Evaluation of patients with implantable cardioverter-defibrillator in a Latin American tertiary center.
المؤلفون: França AT; Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil., Martins LNA; Departamento de estatística da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil., de Oliveira DM; Departamento de Ciência da Computação da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil., de Castilho FM; Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil., Branco BC; Interdisciplinary Laboratory of Medical Investigation, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Wilnes B; Interdisciplinary Laboratory of Medical Investigation, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Ribeiro ALP; Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.; Department of Internal Medicine, Faculdade de Medicina, Belo Horizonte, Brazil., Carmo AALD; Cardiology Service, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
المصدر: Journal of cardiovascular electrophysiology [J Cardiovasc Electrophysiol] 2024 Apr; Vol. 35 (4), pp. 675-684. Date of Electronic Publication: 2024 Feb 07.
نوع المنشور: Observational Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Blackwell Country of Publication: United States NLM ID: 9010756 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1540-8167 (Electronic) Linking ISSN: 10453873 NLM ISO Abbreviation: J Cardiovasc Electrophysiol Subsets: MEDLINE
أسماء مطبوعة: Publication: Malden, MA : Blackwell
Original Publication: Mt. Kisco, N.Y. : Futura Pub., c1990-
مواضيع طبية MeSH: Cardiomyopathies*/etiology , Defibrillators, Implantable*/adverse effects , Tachycardia, Ventricular*/diagnosis , Tachycardia, Ventricular*/therapy , Tachycardia, Ventricular*/etiology, Humans ; Death, Sudden, Cardiac/epidemiology ; Death, Sudden, Cardiac/prevention & control ; Death, Sudden, Cardiac/etiology ; Latin America ; Ventricular Fibrillation/diagnosis ; Ventricular Fibrillation/therapy ; Ventricular Fibrillation/etiology ; Retrospective Studies
مستخلص: Introduction: Despite advancements in implantable cardioverter-defibrillator (ICD) technology, sudden cardiac death (SCD) remains a persistent public health concern. Chagas disease (ChD), prevalent in Brazil, is associated with increased ventricular tachycardia (VT) and ventricular fibrillation (VF) events and SCD compared to other cardiomyopathies.
Methods: This retrospective observational study included patients who received ICDs between October 2007 and December 2018. The study aims to assess whether mortality and VT/VF events decreased in patients who received ICDs during different time periods (2007-2010, 2011-2014, and 2015-2018). Additionally, it seeks to compare the prognosis of ChD patients with non-ChD patients. Time periods were chosen based on the establishment of the Arrhythmia Service in 2011. The primary outcome was overall mortality, assessed across the entire sample and the three periods. Secondary outcomes included VT/VF events and the combined outcome of death or VT/VF.
Results: Of the 885 patients included, 31% had ChD. Among them, 28% died, 14% had VT/VF events, and 37% experienced death and/or VT/VF. Analysis revealed that period 3 (2015-2018) was associated with better death-free survival (p = .007). ChD was the only variable associated with a higher rate of VT/VF events (p < .001) and the combined outcome (p = .009).
Conclusion: Mortality and combined outcome rates decreased gradually for ICD patients during the periods 2011-2014 and 2015-2018 compared to the initial period (2007-2010). ChD was associated with higher VT/VF events in ICD patients, only in the first two periods.
(© 2024 Wiley Periodicals LLC.)
References: Tepper D. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT‐HF). Congestive Heart Failure. 1999;353(9169):2001‐2007. doi:10.1016/S0140-6736(99)04440-2.
Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. J Am Coll Cardiol. 1999;33(3):598‐604. doi:10.1016/S0735-1097(98)00609-3.
Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893‐1906. doi:10.1056/NEJMoa032292.
McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993‐1004. doi:10.1056/NEJMoa1409077.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709‐717. doi:10.1056/NEJM199909023411001.
Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP. Are lipid‐lowering drugs also antiarrhythmic drugs. J Am Coll Cardiol. 2003;42(1):81‐87. doi:10.1016/S0735-1097(03)00498-4.
Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta‐analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18(7):1098‐1105. doi:10.1016/j.hrthm.2021.03.028.
Shuvy M, Qiu F, Lau G, et al. Temporal trends in sudden cardiac death in Ontario, Canada. Resuscitation. 2019;136:1‐7. doi:10.1016/j.resuscitation.2019.01.010.
Connolly S. Meta‐analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21(24):2071‐2078. doi:10.1053/euhj.2000.2476.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225‐237. doi:10.1056/NEJMoa043399.
Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy. JAMA. 2004;292(23):2874. doi:10.1001/jama.292.23.2874.
Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539‐1549. doi:10.1056/NEJMoa050496.
Oliveira GMM, Brant LCC, Polanczyk CA, et al. Estatística cardiovascular—Brasil 2020. Arq Bras Cardiol. 2020;115(3):308‐439. doi:10.36660/abc.20200812.
Braggion‐Santos MF, Volpe GJ, Pazin‐Filho A, Maciel BC, Marin‐Neto JA, Schmidt A. Sudden cardiac death in Brazil: a community‐based autopsy series (2006‐2010). Arq Bras Cardiol. 2015;104(2):120‐127. doi:10.5935/abc.20140178.
Rassi Jr. A, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol. 2001;76(1):86‐96. doi:10.1590/S0066-782X2001000100008.
Nadruz W, Gioli‐Pereira L, Bernardez‐Pereira S, et al. Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure. Heart. 2018;104(18):1522‐1528. doi:10.1136/heartjnl-2017-312869.
Carmo AAL, de Sousa MR, Agudelo JF, et al. Implantable cardioverter‐defibrillator in Chagas heart disease: a systematic review and meta‐analysis of observational studies. Int J Cardiol. 2018;267(2018):88‐93. doi:10.1016/j.ijcard.2018.05.091.
Barbosa MPT, da Costa Rocha MO, de Oliveira AB, Lombardi F, Ribeiro ALP. Efficacy and safety of implantable cardioverter‐defibrillators in patients with Chagas disease. EP Europace. 2013;15(7):957‐962. doi:10.1093/europace/eut011.
Filho MM, De Siqueira SF, Moreira H, et al. Probability of occurrence of life‐threatening ventricular arrhythmias in chagas' disease versus non‐Chagas' disease. probability of occurrence of life‐threatening ventricular arrhythmias in Chagas' disease versus non‐chagas' disease. Pacing Clin Electrophysiol. 2000;23(11P2):1944‐1946. doi:10.1111/j.1540-8159.2000.tb07058.x.
Rabinovich R, Muratore C, Iglesias R, et al. Time to first shock in implantable cardioverter defibrillator (ICD) patients with Chagas cardiomyopathy. Pacing Clin Electrophysiol. 1999;22(1):202‐205. doi:10.1111/j.1540-8159.1999.tb00333.x.
Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta‐blockers, amiodarone plus beta‐blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC study: a randomized trial. JAMA. 2006;295(2):165‐171. doi:10.1001/jama.295.2.165.
Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial. Circulation. 2002;105(5):589‐594. doi:10.1161/hc0502.103330.
Larsen GK, Evans J, Lambert WE, Chen Y, Raitt MH. Shocks burden and increased mortality in implantable cardioverter‐defibrillator patients. Heart Rhythm. 2011;8(12):1881‐1886. doi:10.1016/j.hrthm.2011.07.036.
Villacastı́n J, Almendral J, Arenal A, et al. Incidence and clinical significance of multiple consecutive, appropriate, high‐energy discharges in patients with implanted cardioverter‐defibrillators. Circulation. 1996;93(4):753‐762. doi:10.1161/01.CIR.93.4.753.
Ha AH, Ham I, Nair GM, et al. Implantable cardioverter‐defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm. 2012;9(12):2068‐2074. doi:10.1016/j.hrthm.2012.08.032.
Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016;375(2):111‐121. doi:10.1056/NEJMoa1513614.
Della Bella P, Baratto F, Vergara P, et al. Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? results from the multicenter randomized PARTITA trial. Circulation. 2022;145(25):1829‐1838. doi:10.1161/CIRCULATIONAHA.122.059598.
Arenal Á, Ávila P, Jiménez‐Candil J, et al. Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia. J Am Coll Cardiol. 2022;79(15):1441‐1453. doi:10.1016/j.jacc.2022.01.050.
Romero J, Velasco A, Pisani CF, et al. Advanced therapies for ventricular arrhythmias in patients with chagasic cardiomyopathy. J Am Coll Cardiol. 2021;77(9):1225‐1242. doi:10.1016/j.jacc.2020.12.056.
Wang Y, Zhu H, Hou X, et al. Randomized trial of left bundle branch vs biventricular pacing for cardiac resynchronization therapy. J Am Coll Cardiol. 2022;80(13):1205‐1216. doi:10.1016/j.jacc.2022.07.019.
Carmo AAL, Miranda RC, Lacerda‐Filho A, Ribeiro ALP. Laparoscopic guided epicardial access. Heart Rhythm. 2015;12(2):461‐462. doi:10.1016/j.hrthm.2014.11.039.
Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality. Circ Arrhythm Electrophysiol. 2014;7(1):164‐170. doi:10.1161/CIRCEP.113.001217.
Vaidya VR, Asirvatham R, Kowlgi GN, et al. Trends in cardiovascular implantable electronic device insertion between 1988 and 2018 in olmsted county. JACC Clin Electrophysiol. 2022;8(1):88‐100. doi:10.1016/j.jacep.2021.06.006.
Vieira de Melo RM, de Azevedo DFC, Lira YM, Cardoso de Oliveira NF, Passos LCS. Chagas disease is associated with a worse prognosis at 1‐year follow‐up after implantable cardioverter‐defibrillator for secondary prevention in heart failure patients. J Cardiovasc Electrophysiol. 2019;30(11):2448‐2452. doi:10.1111/jce.14164.
Cardinalli‐Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of all‐cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol. 2007;18(12):1236‐1240. doi:10.1111/j.1540-8167.2007.00954.x.
Rassi A. Implantable cardioverter‐defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial. J Cardiovasc Electrophysiol. 2007;18(12):1241‐1243. doi:10.1111/j.1540-8167.2007.01011.x.
Rassi A, Rassi A. Another disappointing result with implantable cardioverter‐defibrillator therapy in patients with Chagas disease. Europace. 2013;15(9):1383. doi:10.1093/europace/eut092.
Migowski A, Chaves RBM, Coeli CM, et al. Acurácia do relacionamento probabilístico na avaliação da alta complexidade em cardiologia. Rev Saude Publica. 2011;45(2):269‐275. doi:10.1590/S0034-89102011005000012.
فهرسة مساهمة: Keywords: chagas cardiomyopathy; defibrillators; implantable; mortality; tachycardia; ventricular
تواريخ الأحداث: Date Created: 20240207 Date Completed: 20240410 Latest Revision: 20240413
رمز التحديث: 20240414
DOI: 10.1111/jce.16201
PMID: 38323491
قاعدة البيانات: MEDLINE
الوصف
تدمد:1540-8167
DOI:10.1111/jce.16201